than 75 years, respectively. Therapy-related AML is 3-to 7-fold more common in older patients with AML and also confers a poor prognosis. 5, 6 Current clinical trials are finally addressing new treatment approaches to improve the long-term survival of older patients with AML.
The heterogeneity of AML is influenced by the diverse array of genetic mutations that may be acquired by the leukemic cells. Approximately 88% of new diagnoses are associated with either cytogenetic or molecular mutations. A subset of the remaining 12% of cases with normal karyotype and no molecular mutations express an altered copy number of genespecific mRNA. Cytogenetic and molecular abnormalities represent the most predictive, disease-specific risk factor for prognosis. [7] [8] [9] Gene expression profiling using microarray technology has uncovered unique and predictive mRNA and, more recently, microRNA signatures. 10, 11 Data from multiple trials have established 3 strata of risk according to cytogenetic status (Table 1) . Good-risk includes favorable-cytogenetic core-binding transcription factor (CBF) mutations with further molecular substratification by c-KIT status and the subset of patients with normal cytogenetics with an NPM1 mutation in the absence of other mutations. Poor-risk includes loss of chromosome 7, inv(3) or t(3;3), complex cytogenetics, and the subset of normal cytogenetic patients with FLT3-internal tandem duplication (ITD). Intermediate-risk is a heterogeneous group with 5-year overall survival (OS) ranging from 13% to 41% and nearly 200 various mutations, including t(11;19)(q23;p13.1), t(6;11)(q27;q23), and t(6;9)(p23;q34) according to Medical Research Council (MRC) data. Although deletions 7q, 9q, 11q, 20q, and t(9;11)(p22:q23) were categorized as adverse risk by SWOG, they have otherwise been considered intermediate risk. 12 Loss of chromosome Y and normal cytogenetics or diploid karyotype are generally accepted as intermediate risk.
Because 45% of de novo AML has a normal karyotype, efforts to identify molecular abnormalities to risk stratify this largest cytogenetic group have been pursued. Only 23.6% of normal cytogenetic AML is truly wild-type based on molecular testing identifying mutations in genes, including CEBPA and NPM1, which carry favorable prognosis (recently confirmed by Schlenk et al. 13 ), or MLL, FLT3, BAALC, EVI-1, BCL-2, WT-1, and MN-1 that are associated with unfavorable prognosis (Table 2) . Finally, although of unclear influence on clinical outcome, mutations in signaling pathways (particularly in RAS), which occur in 10% to 18% of de novo AML are likely involved in leukemogenesis and will be a target of future therapies. 15, 16 
Treatment
Approach to treatment of acute leukemia has not changed since the institution of combination chemotherapy in 2 treatment phases: induction followed by postremission consolidation. Time to clearance of leukemic blasts with induction therapy influences prognosis. Three risk groups are defined by number of days since initiation of induction therapy required to observe clearance of peripheral blood blasts (≤ day 3, 12.5% relapse risk; day 4 or 5, 47% relapse risk; ≥ day 6, 78% relapse risk). 17 Because of a nearly universal relapse risk within 6 months with induction chemotherapy alone, consolidation therapy is required. Trials have also examined the use of maintenance chemotherapy after consolidation, although its role is not clearly defined. Finally, studies are Optimizing Therapy for Acute Myeloid Leukemia ongoing to determine the proper time to consider stem cell transplantation and incorporation of novel therapies.
Induction
Combination of cytarabine, a cell cycle-specific chemotherapeutic agent, given through continuous infusion for 7 days, and an anthracycline antibiotic (daunorubicin or idarubicin) for 3 days has long been the standard for induction therapy outside of clinical trials. Efforts to improve this regimen, although without success, have included incorporation of high-dose cytarabine, double induction therapy, and addition of other agents, such as etoposide, chlorodeoxyadenosine, and fludarabine.
18-20
The results of 3 trials have shown idarubicin to be superior to daunorubicin. [21] [22] [23] Berman et al. 21 showed a superior complete response (CR) rate and median survival of 80% and 19. 25 Overall response rates (ORRs) and CR rates after the first course of induction were superior in the idarubicin arm, at 83% ORR and 62% CR for 3 days of idarubicin and 78% ORR and 57% CR for 4 days of idarubicin, versus 71% ORR and 45% CR with daunorubicin. Despite the findings, idarubicin shows no clear benefit compared with other anthracyclines.
Mitoxantrone, an anthraquinone, has been compared with standard anthracyclines in older patients with AML with equivalent response and survival. When comparing mitoxantrone with idarubicin or daunorubicin, each in combination with standarddose cytarabine, Rowe et al. 26 found that neither CR rates (observed in 46%, 43%, and 40%, respectively) nor median OS (7.2, 7.5, and 7.7 months, respectively) were statistically different. These results are in contrast to the results of a recent European study randomizing 2157 patients to daunorubicin, mitoxantrone, or idarubicin, with each arm receiving cytarabine and etoposide. CR rates were similar for all 3 arms; however, among patients with no available donor for stem cell transplantation, the idarubicin and mitoxantrone arms showed superior DFS compared with daunorubicin.
Finally, 2 studies examined the role of adding etoposide or fludarabine to the induction regimen. The Australian Leukemia Study (ALSG) added etoposide to daunorubicin and cytarabine, and found no improvement in remission rates. 19 In subset analysis, OS was prolonged in patients younger than 55 years with the addition of etoposide (17 vs. 9 months). The addition of fludarabine or etoposide to idarubicin and cytarabine did not improve outcome, although it resulted in greater efficacy in overcoming P-glycoprotein-mediated MDR. 20 Although cytarabine has been a backbone of induction therapy, a series of trials have addressed its optimal dosing, comparing standard-versus high-dose treatment (Table 3) .
27-29 These 3 trials showed no difference in CR rate, and superior DFS (excluding the subset of patients in SWOG aged 50-64 years), but OS data was heterogeneous. Furthermore, a meta-analysis by Kern and Estey 30 reported no difference in median OS and a 6-fold weighted-mean difference in 4-year OS favoring high-dose cytarabine. Because of the toxicity of high-dose induction chemotherapy, including a nearly 4-fold higher rate of grade 3/4 neurotoxicity, postremission treatment was precluded in a significant subset of patients. High-dose induction chemotherapy use is limited because of the risk for toxicity.
Further dose-intensification in double-induction regimens was tested by the German AML cooperative group (AMLCG), with long-term results recently published. 31 In this large trial, 1770 patients were randomized to double-induction with 2 courses of high-dose cytarabine compared with 1 standard-and 1 high-dose cycle without statistically superior efficacy (53% vs. 70% CR and 19% vs. 42% 3-year OS, respectively).
Consolidation
Recognizing that high-dose induction chemotherapy followed by consolidation produced OS rates as high as 52% among young patients, 28 a CALGB trial attempted to show similar efficacy with less toxicity using high-dose consolidation chemotherapy after standard-dose induction. 32 In this trial, 1088 patients received standard induction with daunorubicin and cytarabine followed by randomization to 1 of 3 doses of cytarabine; 100 mg/m 2 /d for 5 days, 400 mg/m 2 /d for 5 days, or 3000 mg/m 2 every 12 hours (6000 mg/m 2 /d) for 3 days, on days 1, 3, and 5. DFS at 52 months was superior in the high-dose consolidation arm (hazard ratio, 0.67). However, the 4-year DFS benefit seen in patients aged 60 years and younger (44% vs. 24%) was not observed in those older than 60 years (DFS ≤ 16%), partially because the older patients had a 5% treatment-related mortality and 12% severe neurologic toxicity. Subset analysis showed superior DFS with high-dose cytarabine for patients with good-risk cytogenetics, marginal benefit with intermediate-risk cytogenetics, and no benefit with poor-risk cytogenetics ( Fig. 2A-C) . 33 Among patients with CBF-AML treated with high-, intermediate-, and standard-dose cytarabine consolidation, 5-year CR was observed in 78%, 57%, and 16%, respectively. The benefit was less marked among patients with normal-karyotype AML, with no benefit seen in those with poor-risk cytogenetics (21%, 13%, and 13% CR, respectively).
Stein et al. 34 showed improvement in CR with high-dose cytarabine during induction among favorable-, intermediate-, and poor-risk patients (87%, 79%, and 62% CR, respectively). This issue has been revisited by Neubauer et al., 16 who recently showed that patients with RAS mutations who receive highdose cytarabine have fewer relapses compared with those with wild-type mutations (45% vs. 68%). 16 The interdependence of these observations has not been explored.
A series of CALGB trials have addressed the role of high-dose cytarabine consolidation in improving outcome in CBF-AML.
35-37 Extended cycles of consolidation (3 vs. 1) among patients with t(8;21) were associated with superior outcome, with a 19% relapse rate and 76% OS among patients receiving 3 or more cycles versus 62% and 41%, respectively, among those receiving a single cycle. 35 Likewise, among patients with inv(16) or t(16;16), relapse was significantly decreased with extended cycles of consolidation, although no difference in OS was observed. 36 In CALGB 9222, sequential multiagent chemotherapy, including one course of high-dose cytarabine followed by etoposide and cyclophosphamide, and a third course of mitoxantrone and diaziquone, showed no difference in median DFS, 1-year survival, or median OS when compared with 3 cycles of highdose cytarabine. 38 A recent retrospective review of 370 patients by Appelbaum et al. 39 suggests that the superior prognosis associated with CBF-AML may not be as significant as previously reported.
Maintenance
Despite the established role of maintenance therapy in acute lymphoblastic leukemia and acute promyelocytic leukemia, its role in AML is less clear. In 1978, the German AMLCG reported the results of a Abbreviations: ALSG, Australian Leukemia Study Group; AML, acute myeloid leukemia; AMLCG, German Acute Myeloid Leukemia Cooperative Group; CR, complete response; DFS, disease-free survival; DNR, daunorubicin; ED, early death; OS, overall survival; SE, side-effect specifically grade III, IV, or V neurologic toxicity; TG, thioguanine; VP-16, etoposide. *Statistically significant (P < .05).
nonrandomized pilot study of maintenance versus observation, showing an improved 4-year remission rate of 24% versus 0% favoring maintenance therapy. 40 In 1981, Rai et al. 41 published the findings of a CALGB study of 358 patients who underwent standard induction chemotherapy followed by maintenance with cytarabine, 100 mg/m 2 , subcutaneously or intravenously twice daily for 5 days along with either thioguanine, cyclophosphamide, lomustine, or daunorubicin given in monthly cycles for 4 to 5 years. 41 Median survival was 35 months with standard induction and subcutaneous cytarabine, the longest reported survival in a prospective AML trial. Subsequent studies, including AMLCG 81, AMLCG 92, ECOG E5483, SWOG 8124, and AML 9 (HOVON), each confirmed improved DFS, although not OS, with maintenance chemotherapy.
42 Japan Leukemia Study Group AML 87 reported superior DFS, although not OS, after 12 versus 4 cycles of cytarabine, daunorubicin, mercaptopurine, and vincristine maintenance. 44 CALGB 7921 reported a suggestion of worse OS with 3 years versus 8 months of thioguanine and cytarabine maintenance. 45 One caveat to prior negative trials of maintenance chemotherapy is that only standard cytotoxic chemotherapy or IL-2 was used. Trials of molecular targeted therapies, antibody therapeutics, hypomethylating agents, and tyrosine kinase inhibitors as maintenance strategies are ongoing.
Stem Cell Transplantation
Eleven major trials, involving 9109 patients, have examined the role of stem cell transplantation as postremission therapy for AML (Table 4) . 46 The results suggest no convincing role for autologous stem cell transplant as postremission therapy. However This finding contrasts with the retrospective review of 999 patients by Ferrant et al. 57 that observed similar benefit with allogeneic and autologous transplantation for patients with unfavorable karyotype, and a benefit to allogeneic transplantation only in patients with favorable-or standard-risk cytogenetics. 57 Nonetheless, the recent findings are supported by the HOVON/SAKK analysis of 3 prior trials using a "donor versus no donor" approach assessing 2287 patients in first CR, and a meta-analysis of 3103 patients in the MRC, EORTC, BGMT, and HOVON trials. 58 In the meta-analysis, risk for death was significantly reduced by 13% in patients with a donor, a result not identified in any individual study. 58 If postremission therapy with transplantation is selected, additional cycles of consolidation before transplantation seems to be beneficial if a donor is available. 59 Beyond cytogenetics, further stratification of risk groups based on molecular markers suggests that only specific subsets benefit from transplantation. Schlenk et al. 60 evaluated prognosis based on postremission therapy stratified by molecular mutation status for 872 patients with normal-karyotype de novo AML in 4 prior AMLCG trials (AML 2/95, AML 1/99, AML HD93, and AML HD98A). Among patients with normal-karyotype AML, only those experiencing first remission without the molecular phenotype NPM1+/FLT3-ITD-, with the FLT3-ITD+, or with NPM1-/CEBPA-/FLT3-ITD-benefit from allogeneic transplantation 13 ( Fig. 3A, B) . In a similar approach, Power et al. 61 evaluated FLT3-ITD status among 267 patients who underwent transplantation and showed no difference in survival among FLT3-ITD+ and wild-type FLT3 AML, arguing that allogeneic transplantation improved prognosis of AML patients with FLT3 mutations, overcoming the typically negative prognosis of this subset of patients. Finally, current transplant strategies are extending the upper age of transplantation, with 2 promising studies of reduced-intensity transplantation showing OS of 51% and 45% at 3 and 4 years, respectively, in older patients with AML experiencing first or second complete remission. and minimal improvement in prognosis (Fig. 1 ).
2,64
Appelbaum et al. 4 reviewed 5 prior SWOG studies and reaffirmed the association of increasing age with less favorable cytogenetics and poor performance status, factors that contribute to poor outcomes (Fig.  4A-C) . Prior trials attempting to improve prognosis in older patients with AML using strategies such as incorporating growth factor support (ECOG E3993), intensifying cytarabine, and modifying the chemotherapy dosing schedule showed no improved survival. Minor improvement in CR rates has been achieved through incorporating alternative cytotoxic chemotherapeutics, including thioguanine in MRC AML 11, mitoxantrone and etoposide in SWOG 9333, and modified idarubicin and cytarabine in the M. D. Anderson case series reported by Estey et al. 65 Each of these advances is limited by short durability of response. In older patients with AML, maintenance chemotherapy trials, including combination of thioguanine, cytarabine, and daunorubicin, failed to improve OS, although median DFS increased from 12 to 19 months.
66 At 4 to 5 years, only 13% of the 297 patients remained in CR. ALFA 9803, randomized patients aged 65 years and older to idarubicin or daunorubicin with either a single cycle or 6 cycles of maintenance chemotherapy. No difference between anthracyclines was observed, and despite improved DFS with maintenance, no OS benefit was shown. Results of MRC AML 14 reported in 2005 showed a 5-year DFS of only 13%, which was identical to that reported a decade earlier.
New agents for older patients with AML have the most promise for improving OS in this poor-risk subset. Agents recently approved or currently in trials include gemtuzumab ozogamycin, clofarabine, tipifarnib, cloretazine, MDR inhibitors, bcl-2 antisense, and hypomethylating agents.
Novel Agents
Newer therapies include gemtuzumab ozogamycin, a calicheamicin-conjugated monoclonal antibody directed toward CD33 approved for patients aged 60 years and older experiencing their first recurrence after a CR of at least 3 months. 67 Gemtuzumab monotherapy has also been assessed in previously untreated, older patients with AML, including 16 with a 25% CR rate. Dose-limiting hepatotoxicity and bone marrow suppression was observed, along with neutropenic fever in 10 of 16 patients. 68 Pirrotta et al. 69 piloted combination induction incorporating gemtuzumab in 12 patients, using a regimen that also included fludarabine, cytarabine, and idarubicin, followed by 2 courses of consolidation with gemtuzumab. CRs were observed in 75% of patients with no treatment-related mortality. Similarly, incorporating gemtuzumab into standard induction with daunorubicin and cytarabine produced a 38% CR and 12.5% partial response rate among a limited cohort of patients.
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In a report of findings from MRC AML 15, Burnett et al. 71 focused on the role of gemtuzumab in either induction or consolidation in younger patients with previously untreated AML, with induction including randomization to daunorubicin and cytarabine; cytarabine, daunorubicin, and etoposide; or cytarabine, idarubicin, fludarabine, and granulocyte colonystimulating factor. Consolidation involved amsacrine and etoposide or high-dose cytarabine. Among 1115 randomized patients, 83% expressed CD33. Although no difference in OS was seen at 15 months, the rate of relapse decreased from 52% to 37% at 3 years. The benefit to treatment seemed limited to patients with favorable-and intermediate-risk cytogenetics. As this trial matures, patients continue to be followed-up for OS. A small subset of approximately 140 patients in this trial were at least 60 years old, in whom a striking CR rate of 82% was observed. At least 7 trials are currently examining the role of gemtuzumab as maintenance therapy, consolidation therapy before autologous stem cell transplantation, part of induction, and monotherapy in previously untreated older patients.
Clofarabine is an adenosine nucleoside analog approved for pediatric acute lymphoblastic leukemia. A phase II adult trial reported a 60% ORR and 52% CR rate with clofarabine in combination with cytarabine as induction therapy in newly diagnosed AML, with an acceptable 7% treatment-related mortality.
72
Among patients previously untreated and unfit for standard induction, clofarabine monotherapy has reasonable initial efficacy, with a 48% CR. 73 Troxacitabine, a nucleoside analog, with 13% ORR in phase I trials, has been shown to produce 40% to 55% CR in combination with cytarabine or idarubicin in older patients with newly diagnosed AML with unfavorable karyotype. 74 Cloretazine, a sulfonylhydrazine alkylator, has efficacy as monotherapy, as reported in trials CLI-033 and -043. Among 53 patients, including 93% with intermediate-or high-risk cytogenetics, 2 experienced a CR with a 31% ORR.
75
Molecular targeted therapies include several inhibitors of FLT3 kinase. FLT3 is an FMS-like tyrosine kinase that influences myeloid differentiation and has 2 common mutational positions. FLT3-ITD within the juxtamembrane domain occurs in 20% to 30% of patients with AML, whereas mutations in the tyrosine kinase domain occur in 5% to 10%. FLT3-ITD confers a negative prognosis, with worse OS and higher relapse rate, that is influenced by loss of underlying wild-type FLT3 and possibly by size and copy number of ITDs in the mutant allele. An oral FLT3 inhibitor CEP701 (lestaurtinib) is being evaluated in the salvage setting with an improved response rate seen in preliminary results. in older patients with AML who are otherwise not candidates for standard induction regimens.
77
In a phase II trial, oral CEP701 was well tolerated for 8 weeks, with transfusion independence in 60% of patients with FLT3 mutations and 23% in wild-type FLT3. PKC412, a second targeted FLT3 inhibitor, has shown favorable CR rates (92% for mutated and 69% for wild-type FLT3) in combination with standard induction chemotherapy in young patients. 78 Mutations in exon 17 of KIT, which encodes the activation loop, are associated with reduced median OS from 1836 to 304 days in patients with CBF-AML. Inhibition of other kinases, including c-KIT, may show efficacy in a subset of CBF-AML, with one trial involving dasatinib, a c-KIT inhibitor, currently ongoing.
Tipifarnib (R115777), a farnesyl transferase inhibitor, was used in combination with standard induction, consolidation, and maintenance chemotherapy without improvement in CR rates. In older patients with untreated AML, phase II studies showed a 14% CR rate and 23% ORR. 79 Nonhematologic serious adverse effects were observed in 47% of patients, potentially limiting its use in the older population. When used in combination with etoposide as induction for older patients with AML, CRs occurred in 25%. 80 Because of the increased incidence of MDR efflux mechanisms in older AML patients, multiple new agents targeting this mechanism of drug resistance are currently in trials. This strategy was validated by the use of cyclosporine A (CsA) to inhibit MDR in a randomized phase III SWOG trial for relapsed or refractory AML.
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DFS and OS at 2 years both improved significantly with CsA (34% vs. 9%, and 22% vs. 12%, respectively). This finding was further supported by the SWOG study of high-risk patients, in which CR rate was independent of P-glycoprotein status, and serum daunorubicin levels were increased in the group receiving the MDR modulator. 82 However, in the ECOG 2995 trial of patients with poor-risk AML and high-risk MDS, no benefit in response rate was seen in those receiving PSC-833, an MDR modulator. 83 In CALGB 9720, PSC-833 combined with daunorubicin, etoposide, and cytarabine led to excessive mortality compared with the PSC-833 arm (44% vs. 20%, respectively), requiring early trial termination. Zosuquidar, a third-generation MDR modulator, developed as a more specific P-glycoprotein inhibitor, was used along with standard chemotherapy in ECOG 3999. No difference was observed in overall or median survival with or without zosuquidar (7.7 vs. 9.4 months, respectively). 84 In a separate trial, 62 patients specifically with P-glycoprotein+ AML received zosuquidar and achieved CR or near CR in 48%, with ORR in 57%. 85 In 3 CALGB trials, 5-azacitidine, a hypomethylating agent, showed reasonable efficacy and a tolerable toxicity profile. 86 CRs were observed in 10% to 17% of patients with myelodysplasia or AML, with hematologic improvements in an additional 23% to 36%. Median survival of patients with AML was 19 months, compared with 13 months in patients receiving placebo. Decitabine or 5-aza-2-deoxycitidine, a similar pyrimidine analog, induced overall responses in 32% of 50 patients with relapsed or refractory AML. 87 The combination of azacitidine with a histone deacetylase inhibitor, MGCD0103, may have a role through modulation of the epigenetic status of AML. A pilot study showed a 30% ORR, with 4 CRs. A second combination study with azacitidine incorporated gemtuzumab in older patients with AML or high-risk myelodysplasia, showing a 76% CR rate and a median response duration of 7 months. 88 Efforts to target leukemic stem cells seem promising. Although early trials of oblimersen, a BCL-2 inhibitor, were positive, the phase III CALGB 10201 trial failed to show a benefit, resulting in early study closure. Because of expression of IL3-R␣ (CD123) by leukemic stem cells, phase I trials of IL-3 in combination with diphtheria toxin are ongoing. In a phase I trial of diphtheria toxin-IL-3 fusion protein among 40 patients, antibody development occurred in most by day 40, but only 1 CR and 1 PR were observed. 89 Parthenolide is a sesquiterpene lactone that selectively induces leukemic stem cell apoptosis in vitro. An orally bioavailable parthenolide has been reported to show promising preclinical activity, but must be studied in clinical trials to determine its safety and efficacy. Multiple other potential leukemia stem cell targets are being actively explored, including CD44, CXCR4, CD123, and NF-kappaB.
Conclusions
The next decade of optimizing AML therapy will incorporate new cytotoxic and novel targeted therapies into the standard approach for AML treatment, because today they remain limited to clinical trials. Stratification of patient risk and selection of therapy has benefited greatly by technologic advances in cytogenetic and molecular assessment. Technical innovations within the next decade may allow continuous monitoring of minimal residual disease. Current molecular and immunophenotyping methodologies can detect evidence of leukemic clones in 80% of patients at levels not possible using standard morphology, metaphase cytogenetics, or interphase fluorescence in-situ hybridization. Preliminary findings from the MRC AML 15 trial show that real-time quantitative PCR allows detection of minimal residual disease in CBF-AML and predicts early relapse. 90 Assuming that minimal phenotype shift of the leukemic clone occurs with treatment and over extended periods and that early institution of therapy can improve OS, the ability to monitor minimal residual disease offers the promise of novel pre-emptive treatment strategies. Finally, future optimization of treatment approaches to AML will include efforts to expedite drug approval and properly define study end points incorporating CR without platelet recovery, markers of minimal residual disease, measures of "bridge to transplant," and patient quality-of-life metrics.
